Literature DB >> 8296798

alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.

P L Bockenstedt1, J T Santinga, S F Bolling.   

Abstract

Idiopathic hypereosinophilic syndrome (HES) is a poorly understood disorder characterized by a markedly elevated peripheral blood eosinophil count in the absence of known associated causes of hypereosinophilia. Idiopathic hypereosinophilic syndrome is associated with eosinophil-induced organ damage, including endomyocardial and pulmonary fibrosis, stroke, and gastrointestinal disease. Treatment of idiopathic HES is centered on the reduction of peripheral circulating eosinophils in an effort to diminish tissue infiltration and destruction. Multiple cytotoxic agents have been tried, with variable results. Prednisone and hydroxyurea have remained the therapies of choice in long term treatment of idiopathic HES. We report here the successful 2 year treatment of aggressive idiopathic HES, refractory to hydroxyurea and prednisone, with alpha-interferon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8296798     DOI: 10.1002/ajh.2830450311

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

Review 1.  Interferon-alpha in childhood haematological malignancies.

Authors:  R Simkó; K Nagy
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 2.  Idiopathic hypereosinophilic syndrome in children: 3 cases with review of literature.

Authors:  Jayashree Kanthila; Nalini Bhaskaranand
Journal:  Indian J Pediatr       Date:  2012-06-28       Impact factor: 1.967

3.  [Spectrum of hypereosinophilia syndrome based on 2 clinical case reports].

Authors:  H Nolte; U Helmchen
Journal:  Med Klin (Munich)       Date:  1998-07-15

4.  Control of hypereosinophilic syndrome-associated recalcitrant coronary artery spasm by combined treatment with prednisone, imatinib mesylate and hydroxyurea.

Authors:  Joseph H Butterfield; Scott W Sharkey
Journal:  Exp Clin Cardiol       Date:  2006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.